Interferon inducing genetically engineered attenuated viruses

Details Interferon inducing genetically engineered attenuated viruses Interferon inducing genetically engineered attenuated viruses

2005-03-15

2005-03-15

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S199100, C424S210100, C424S093100, C435S320100, C435S091400, C435S091320, C435S091520, C435S091420, C435S069100, C514S04400A

Reexamination Certificate

active

06866853

ABSTRACT:
The present invention relates to genetically engineered attenuated viruses and methods for their production. In particular, the present invention relates to engineering live attenuated viruses which contain a modified NS gene segment. Recombinant DNA techniques can be utilized to engineer site specific mutations into one or more noncoding regions of the viral genome which result in the down-regulation of one or more viral genes. Alternatively, recombinant DNA techniques can be used to engineer a mutation, including but not limited to an insertion, deletion, or substitution of an amino acid residue(s) or an epitope(s) into a coding region of the viral genome so that altered or chimeric viral proteins are expressed by the engineered virus.

REFERENCES:
patent: 4071618 (1978-01-01), Konobe et al.
patent: 4659569 (1987-04-01), Mitsuhashi et al.
patent: 5166057 (1992-11-01), Palese et al.
patent: 5854037 (1998-12-01), Palese et al.
patent: 5866694 (1999-02-01), Katinger et al.
patent: 6468544 (2002-10-01), Egorov et al.
patent: 0 702 085 (1996-03-01), None
patent: 0 780 475 A1 (1997-06-01), None
patent: 59-39831 (1984-03-01), None
patent: WO 9634625 (1996-11-01), None
patent: WO 9706270 (1997-02-01), None
patent: WO 9712032 (1997-04-01), None
patent: WO 9802530 (1998-01-01), None
patent: WO 9813501 (1998-04-01), None
patent: WO 9853078 (1998-11-01), None
patent: WO 9902657 (1999-01-01), None
patent: WO 9915672 (1999-04-01), None
Cruse et al, Illustrated Disctionary of Immunology, second edition, edited by Cruse et al. 2003, CRC press, pp. 367 under knockout gene.*
Talon et al. PNAS, 2000, vol. 96, No. 8, pp. 4309-4314.*
Rober-Guroff et al. J. Virol. 1998, vol. 72, pp. 10275-10280.*
Mwau et al. J. Gene. Med. 2003, vol. 5, pp. 3-10.*
Finn, O.L Nature 2003, vol. 3, pp. 630-641.*
Aoki K et al., “Differential sensitivity of two related viruses, Newcastle disease virus and Sendai virus, to interferon in mouse Had-2 cells selective inhibition of translation of NDV mRNA.”, Arch Virol. 1996;141(10):1847-62.
Baez M et al., “Complete nucleotide sequence of the influenza A/PR/8/34 virus NS gene and comparison with the NS genes of the A/Udorn/72 and A/FPV/Rostock/34 strains”, Nucleic Acids Res. Dec. 11, 1980;8(23):5845-58.
Beatrice et al., “Immunogenicity in mice of temperature-sensitive mutants of vesicular stomatitis virus: early appearance in bronchial secretions of an interferon-like inhibitor”, J Gen Virol. 1980; 47:529-533.
Belardelli F and Gresser I, “The neglected role of type I interferon in the T-cell response: implications for its clinical use”, Immunol Today. Aug. 1996;17(8):369-72.
Buonagurio DA et al., “Evolution of human influenza A viruses over 50 years: rapid, uniform rate of change in NS gene”, Science. May 23, 1986:232(4753):980-2.
Butterfield et al., “Vaccination for fowl plague”, Am J Vet Res. Apr. 1978; 39 (4):671-674.
Chen Z et al., “Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3′-end processing machinery”, EMBO J. Apr. 15, 1999;18(8):2273-83.
Crowe JE, “Immune responses of infants to infection with respiratory viruses and live attenuated repiratory virus candidate vaccines”, Vaccine. Aug. 1998; 16(14/15):1432-1432.
de la Luna S et al., “Influenza virus NS1 protein enhances the rate of translation initiation of viral mRNAs”, J Virol. Apr. 1995; 69(4):2427-33.
Desmyter J et al., “Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero)”, J Virol. Oct. 1968;2(10):955-61.
Diaz MO et al., “Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines”, Proc Natl Acad Sci U S A. Jul. 1998;85(14):5259-63.
Durbin JE et al., “Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease”, Cell. Feb. 9, 1996;84(3):442-50.
Egorov A et al., “Transfectant influenza A viruses with long deletions in the NS1 proteins grow efficiently in Vero cells”, J Virol. Aug. 1998;72(8):6437-41.
Egorov AY et al., “Generation of influenza A transfectant viruses containing deletions of the carboxyl-terminal part of the NS1 protein”, inEmergence and Re-emergence of Negative Strand Viruses, Tenth International Conference on Negative Strand Viruses. 1997, Dublin, Ireland. Abstract No. 108, p. 104.
Egorov Alu et al., “[The NS gene—a possible determinant of apathogenicity of a cold-adapted donor of attenuation A/Leningrad/134/47/57 and its reassortants]”, Vopr Virusol. Sep.-Oct. 1994;39(5):201-5. Russian.
Enami M and Palese P, “High-efficiency formation of influenza virus transfectants”, J Virol. May 1991;65(5):2711-3.
Enami M et al., “An influenza virus containing nine different RNA segments”, Virology. Nov. 1991; 185(1):291-8.
Enami K et al., “Influenza virus NS1 protein stimulates translation of the M1 protein”, J Virol. Mar. 1994;68(3):1432-7.
Fodor E et al., “Attenuation of influenza A virus mRNA levels by promoter mutations”, J Virol. Aug. 1998;72(8)6283-90.
Fortes P et al., “Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport”, EMBO J. Feb 1, 1994;13(3):704-12.
Garcia-Sastre A et al., “Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems”, Virology. Dec. 20, 1998; 252(2):324-30.
Garcia-Sastre A et al., “The role of interferon in influenza virus tissue tropism”, J Virol. Nov. 1998;72(11):8550-8.
Goodpasture et al. “The cultivation of vaccine and other viruses in the chorioallantoic membrane of chick embryos”, Science. 1984; 74(1919):371-372.
Haller O et al., “Genetic resistance to influenza virus in wild mice”, Curr Top Microbiol Immunol. 1986;127:331-7.
Haller O et al., “Host gene influences sensitivity to interferon action selectively for influenza virus”, Nature. Feb. 14, 1980; 283(5748):660-2.
Haller O., “Inborn resistance of ice to orthomyxoviruses”, Curr Top Microbiol Immunol. 1981;92:25-52.
Hatada E et al., “Binding of influenza A virus NS1 protein to dsRNA in vitro”, J Gen Virol. Dec. 1992;73 (Pt 12):3325-9.
Krug and Soeiro, 1975, “Studies on the intranuclear localization of influenza virus-specific proteins”, Virology 64:378-87.
Krug, 1995, “Chapter 8. Unique Functions of the NS1 Protein” in Textbook of Influenza, Nicholson et al. (eds.), pp. 82-92.
Li X and Palese P, “Characterization of the polyadenylation signal of influenza virus RNA”, J Virol. Feb. 1994;68(2):1245-9.
Li X and Palese P, “Mutational analysis of the promoter required for influenza virus virion RNA synthesis”, J Virol. 1992 Jul.;66(7):4331-8.
Lu Y et al., “The influenza virus NS1 protein: a novel inhibitor of pre-mRNA splicing”, Genes Dev. Aug. 1, 1994;8(15):1817-28.
Lu Y et al., “Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor”, Virology. Dec. 1, 1995:214(1):222-8.
Luo GX et al., “The polyadenylation signal of influenza virus RNA involves a stretch of uridines followed by the RNA duplex of the panhandle structure”, J Virol Jun. 1991;65(6):2861-7.
Luytjes W et al., “Amplification, expression and packaging of foreign gene by influenza virus”, Cell. Dec. 22, 1989;59(6):1107-13.
Marion RM et al., “The N-terminal half of influenza virus NS1 protein is fully active both in mRNA nuclear retention and enhancement of translation”, inEmergence and Re-emergence of Negative Strand Viruses, Tenth International Conference on Negative Strand Viruses.1997, Dublin, Ireland. Abstract No. 240, p. 170.
Marion RM et al., “The N-terminal half of the in

Affiliated with

Also associated with

Rating

Interferon inducing genetically engineered attenuated viruses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Interferon inducing genetically engineered attenuated viruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon inducing genetically engineered attenuated viruses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3391367